Clinical Trial Update: Rho Kinase (ROCK) Inhibitor in Tauopathies - 1 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for a Rho kinase (ROCK) inhibitor being studied in tauopathies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corticobasal Syndrome
• Progressive Supranuclear Palsy

Drugs mentioned

• Rho kinase (ROCK) inhibitor

Snippet

Sponsor: Woolsey Pharmaceuticals | Conditions: Progressive Supranuclear Palsy, Corticobasal Syndrome | Phase 2 | Status: UNKNOWN